Day One Biopharmaceuticals Inc(DAWN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 12.31% | Shs Outstand | 103.0M | Perf Week | - |
| Market Cap | 2.22B | Forward P/E | - | EPS next Y | 78.57% | Insider Trans | -0.5% | Shs Float | 90.6M | Perf Month | 0.42% |
| Enterprise Value | 1.79B | PEG | - | EPS next Q | -0.11 | Inst Own | 67.73% | Short Float | 7.26% | Perf Quarter | 105.44% |
| Income | -0.11B | P/S | 14.06 | EPS this Y | 59.62% | Inst Trans | -10.28% | Short Ratio | 1.66 | Perf Half Y | 194.93% |
| Sales | 0.16B | P/B | 5.03 | EPS next 5Y | - | ROA | -19.68% | Short Interest | 6.58M | Perf YTD | 131.01% |
| Book/sh | 4.28 | P/C | 5.04 | EPS past 3/5Y | 21.77% -9.72% | ROE | -22.74% | 52W High | 0% ($21.53) | Perf Year | 193.72% |
| Cash/sh | 4.27 | P/FCF | - | Sales past 3/5Y | - | ROIC | -24.18% | 52W Low | 282.08% ($5.64) | Perf 3Y | 57.15% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -0.47% | Gross Margin | 89.12% | Volatility(W/M) | 0.11% 0.16% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 11.29 | Sales Y/Y TTM | 20.6% | Oper. Margin | -80.76% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.91 | EPS Q/Q | 68.21% | Profit Margin | -67.85% | RSI (14) | 80.32 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.02 | Sales Q/Q | 83.92% | SMA20 | 0.36% ($21.45) | Beta | -1.64 | Target Price | $21.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/2/24 | SMA50 | 19.55% ($18.01) | Rel Volume | 0 | Prev Close | $21.53 |
| Employees | 178 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -41.03% 7.75% | SMA200 | 102.18% ($10.65) | Avg Volume(3M) | 3.97M | Price | $21.53 |
| IPO | 2021/5/27 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧠 This is a commercial-stage biopharmaceutical company revolutionizing the treatment of pediatric brain tumors. It has successfully established 'Ojemda' in the market—the world's first treatment for pediatric low-grade glioma (pLGG)—and is preparing for a new leap forward following its recent acquisition by the global pharmaceutical company Servier.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
DAWN has a sound balance sheet but weak earning power
Of every $100 in sales, $80.76 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,406. Peers typically go for $1,297.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +57.1%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 67.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #83 of 599 in the industry
Based on market cap of $2B.
FAQ
DAWN belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of DAWN is approximately $2.2B, ranking 1,995 within its sector.
DAWN has recorded a 52-week high of $21.53 and a low of $5.64.